WO2007059530A2 - Antiperspirant compositions - Google Patents

Antiperspirant compositions Download PDF

Info

Publication number
WO2007059530A2
WO2007059530A2 PCT/US2006/060987 US2006060987W WO2007059530A2 WO 2007059530 A2 WO2007059530 A2 WO 2007059530A2 US 2006060987 W US2006060987 W US 2006060987W WO 2007059530 A2 WO2007059530 A2 WO 2007059530A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
aluminum
salt
zirconium
acid
Prior art date
Application number
PCT/US2006/060987
Other languages
French (fr)
Other versions
WO2007059530A3 (en
Inventor
Jairajh Mattai
Latonya Kilpatrick-Liverman
Marian Holerca
Xiozhong Tang
Original Assignee
Colgate-Palmolive Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007059530(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colgate-Palmolive Company filed Critical Colgate-Palmolive Company
Priority to BRPI0618736-6A priority Critical patent/BRPI0618736A2/en
Priority to AU2006315119A priority patent/AU2006315119B2/en
Priority to CA2629042A priority patent/CA2629042C/en
Priority to ES06846328.0T priority patent/ES2442252T3/en
Priority to EP06846328.0A priority patent/EP1948317B1/en
Priority to PL06846328T priority patent/PL1948317T3/en
Publication of WO2007059530A2 publication Critical patent/WO2007059530A2/en
Publication of WO2007059530A3 publication Critical patent/WO2007059530A3/en
Priority to ZA2008/04051A priority patent/ZA200804051B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/28—Zirconium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/51—Chelating agents

Definitions

  • Antiperspirant compositions containing aluminum or aluminum-zirconium salts tend to exhibit polymerization of these salts over time, forming species with molecular weights ranging from about 500 to about 500,000 g/mol. In general, lower molecular weight species have greater antiperspirant effect than higher molecular weight species. Without being bound by theory, it is believed that the smaller molecules more readily and more effectively occlude sweat pores, thereby producing the desired antiperspirant effect. Thus, reducing the size of the polymers enhances the antiperspirant effect and moreover lowers the amount of antiperspirant salt that is necessary to control perspiration. The ability to reduce the amount of antiperspirant salt in a formulation without compromising efficacy would bring several advantages. Antiperspirant salts are a relatively expensive component of a typical antiperspirant formulation. It is thus very desirable to have compositions wherein antiperspirant salts are stabilized to reduce polymerization.
  • SEC size exclusion chromatography
  • GFC gel filtration chromatography
  • Passage of small molecules through an SEC column is retarded while large molecules pass through more rapidly.
  • Elution time of a polymeric substance migrating through the SEC column is correlated with the size of the polymer molecules, and this relationship allows the apparent molecular weight of a polymer to be determined.
  • 4 to 6 well defined groups of polymerized species in aluminum or aluminum-zirconium salt compositions can be identified by SEC and are commonly known as peaks 1, 2, 3, 4, 5, and 6 (6 is not always present). Peak 1 is associated with zirconium species and so is present only for aluminum-zirconium salts.
  • Peak 2 is not always present in the case of aluminum-zirconium salts. Peak 6 is not always present. The earlier peaks (1, 2, and 3) correspond to the larger species and the later peaks (4, 5 and 6) correspond to the smaller and more desirable species. Peaks correlate with weight average values of molecular weight for polymers, not as discrete values.
  • compositions wherein formation of higher molecular weight zirconium and/or aluminum polymeric species is reduced or suppressed, particularly where such reduction or suppression leads to enhanced efficacy, for example related to more effective occlusion of sweat pores.
  • An antiperspirant composition comprising a mixing product of:
  • the antiperspirant composition comprises a mixing product of:
  • the components of antiperspirant composition may be present in free or salt form, and depending on the formulation, may be precipitated or dissolved or in the form of solvates.
  • the aluminum or aluminum-zirconium salts may be present for example in chloride or chlorohydrate form, e.g. , aluminum chloride, aluminum chlorohydrate, aluminum sequichlorohydrate, aluminum dichlorohydrate, aluminum zirconium tricchlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium octachlorohydrate, or mixtures thereof.
  • these salts may form or be provided as complexes with other compounds, for example complexes with the hydroxy acids and/or quaternary ammonium acids as described, and/or amino acids, such as glycine, and/or polyhydric alcohols, e.g., ethylene glycol, polyethylene glycol, propylene glycol, or polypropylene glycol.
  • the antiperspirant comprises an aluminum-zirconium salt
  • the salt may, for example, have a molar ratio of aluminum to zirconium of about 2 to about 10, for example, about 2 to about 5, or about 5 to about 10.
  • the aluminum-zirconium salt may for example be an aluminum- zirconium chlorohydrate salt or complex thereof, wherein the molar ratio of (Aluminum and Zirconium) to chloro atoms is about 0.9 to about 2.1, for example, about 1.2 to about 1.8.
  • the quaternary ammonium acid compound typically exists in zwitterionic form, forming an inner salt between cationic quaternary ammonium portion and the anionic carboxylic acid portion. It may however be present in salt form, e.g., acid addition salt form.
  • betaine may be provided in the form of betaine hydrochloride.
  • the divalent metal cation may be provided in salt or oxide form, for example calcium may be provided in the form of, e.g., calcium chloride or calcium oxide.
  • the antiperspirant salt is an aluminum-zirconium chlorohydrate salt and the quaternary ammonium acid is betaine, wherein the metal (Aluminum and Zirconium) to chloride ratio is about 0.9 to about 2.1, the betaine to zirconium ratio is about 0.1 to about 2, and the betaine to hydroxy acid ratio is about 0.2 to about 30.
  • the composition exhibits improved stability compared to analogous formulations lacking a hydroxy acid or lacking a hydroxy acid and a divalent cation, e.g., as measured by at least one of (a) a reduction in formation of higher molecular weight polymerized aluminum and/or zirconium species as indicated at least by reduction in area of SEC peaks 2 and/or 3 and/or increase in area of SEC peaks 4 and/or 5; (b) a reduction in formation of higher molecular weight polymerized zirconium species as indicated at least by reduction in area of SEC peak 1; or (c) an increase in peak 5 as compared to peak 4.
  • a reduction in formation of higher molecular weight polymerized aluminum and/or zirconium species as indicated at least by reduction in area of SEC peaks 2 and/or 3 and/or increase in area of SEC peaks 4 and/or 5
  • a reduction in formation of higher molecular weight polymerized zirconium species as indicated at least by reduction in area of SEC peak 1
  • compositions when analyzed by SEC as a 5% aqueous solution using conditions capable of resolving the Aluminum and/or Zirconium species into at least 4 successive peaks exhibit a ratio of the SEC area of the first major peak (peak 1, largest polymer) to the SEC area of the last major peak (usually peak 5) of less than about 1 , and in another embodiment of less than about 0.25.
  • a method for controlling perspiration comprising applying to skin an antiperspirant effective amount of the antiperspirant compositions as described above.
  • antiperspirant compositions obtained or obtainable by the foregoing process.
  • an antiperspirant and/or deodorant formulation for topical use comprising at least one stabilized antiperspirant compositions in combination with a cosmetically acceptable carrier.
  • Such formulations may be as known in the art, e.g., in the form of a stick, gel, cream, liquid roll-on, or aerosol spray. Examples of formulations comprising the stabilized antiperspirant compositions of the invention are provided below.
  • SEC peak areas are used as indicators of aluminum and zirconium polymer size in antiperspirant salt solutions. It is believed, without being bound by theory, that enhanced antiperspirant and/or deodorant efficacy is associated with increase in peak 4 and/or peak 5 area relative to peak 2 and/or peak 3 area, and with decrease in peak 1 area, indicating a lower degree of polymerization of the aluminum and zirconium species respectively. Relative areas of peaks 1 through 5 constitute the "SEC profile", as that term is used herein, of an antiperspirant and/or deodorant composition.
  • Stabilized compositions of the invention maintain, over a period of time, improved SEC profiles, indicating a lower degree of polymerization of the aluminum and/or zirconium species after aging, by comparison with non-stabilized compositions, for example compositions lacking a calcium salt and/or a hydroxy acid.
  • Peak areas can be adjusted based on an internal standard, with total aluminum peak area (sum of peaks 2 through 5) as the common denominator. This is possible as total aluminum peak area remains constant. Adjusting peak areas to an internal standard in this fashion better reflects the polymer distribution in the sample.
  • the relative amounts of components (a), (b), and (c) of the antiperspirant composition as described above can be such that an aqueous solution of these components in the same relative amounts, at a 25% concentration of (a) + (b), following aging of the solution at about 45°C for about 60 days, has an adjusted SEC peak 1 area of no more than about 40%, for example no more than about 20%, or no more than about 10%.
  • the relative amounts of components (a), (b), and (c) as described above are such that an aqueous solution of these components in the same relative amounts, at a 25% concentration of (a) + (b), following aging of the solution at about 45 0 C for about 60 days, has an adjusted SEC peak 5 area of at least about 30%, for example at least about 40%.
  • the relative amounts of components (a), (b), and (c) as described above are such that an aqueous solution of these components in the same relative amounts, at a 25% concentration of (a) + (b), following aging of the solution at about 45 0 C for about 60 days, has an adjusted SEC peak 4 area of at least about 15%.
  • the adjusted SEC peak 4 area is optionally not more than about 25%.
  • the relative amounts of components (a), (b), and (c) as described above are such that an aqueous solution of these components in the same relative amounts, at a 25% concentration of (a) + (b), following aging of the solution at about 45°C for about 60 days, has:
  • the aluminum or aluminum-zirconium salt of the antiperspirant compositions of the invention can be present in the final topical formulation in any suitable total amount, typically about 4% to about 35%, for example about 10% to about 25%, or about 15% to about 20%, by weight of the formulation. It will be understood that while amounts in various ranges of aluminum salts, aluminum-zirconium salts or complexes thereof are indicated herein, lesser amounts can be used to contribute to deodorant activity of deodorant products which are not classified as antiperspirants.
  • the antiperspirant compositions of the invention also comprise a quaternary ammonium acid compound, e.g., an alpha — quaternary ammonium-carboxylic acid, for example, betaine.
  • Betaine is l-carboxy-N,N 5 N-trimethylmethanaminium hydroxide inner salt (IUPAC nomenclature), and is zwitterionic. It occurs naturally in many foodstuffs and can also be synthesized. Though sometimes incorrectly referred to as an amino acid, it will be understood that betaine is not truly an amino acid.
  • a "betaine component" herein can be betaine or a salt thereof. In certain embodiments, the betaine component comprises betaine, betaine hydrochloride or a mixture thereof.
  • the betaine component may, for example, be present in the final formulation for topical use in a total amount of about 0.5 to about 20% for example about 5% to about 15%, by weight.
  • the molar ratio of betaine to zirconium may be about 0.1 to about 2, for example, about 0.1 to about 1.
  • composition of the invention may also optionally comprise at least one divalent cation, e.g. in the form of a salt.
  • this cation is a calcium salt or oxide, e.g., calcium chloride, calcium bromide, calcium nitrate, calcium acetate, calcium formate, calcium gluconate, calcium ascorbate, calcium lactate, calcium glycinate, calcium citrate, calcium carbonate, calcium oxide, calcium hydroxide, calcium phosphate, calcium phosphonate, calcium picrolonate, calcium sulfate, calcium sulfonate, calcium sulfocyanate, calcium perrhenate or mixtures thereof.
  • the calcium salt comprises an anion having a linear or branched Ci_ 6 o alkyl or alkenyl chain and at least one functional moiety capable of binding a calcium ion.
  • the at least one functional moiety can be a nitrate, sulfate, sulfonate, carbonate, carbonyl, phosphate, phosphonate or hydroxyl moiety.
  • the anion can comprise one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, such heteroatoms being part of the chain and/or part of the functional moiety.
  • the divalent cation when the divalent cation is provided in the form of a salt, it may be present in the final formulation in a total amount of about 0.2% to about 10%, for example about 2% to about 8%, by weight.
  • the molar ratio of the divalent metal ion to the aluminum or (Aluminum and Zirconium) may be about 0.02 to about 1.2, for example about 0.1 to about 0.8.
  • the composition also comprises at least one hydroxy acid.
  • Illustrative hydroxy acids include ⁇ -hydroxy acids, ⁇ -hydroxy acids and mixtures thereof.
  • the hydroxy acid is chosen from lactic acid, glycolic acid, lactobionic acid, carnitine, salicylic acid and mixtures thereof.
  • the alpha-hydroxy acid has a pIQ of about 4.5 or less, about 2.5 to about 4.5, or about 3.5 to about 4.0.
  • the at least one hydroxy acid is present in a total amount of about 0.2% to about 10%, for example about 0.5% to about 9%, or about 2% to about 8%, by weight.
  • the molar ratio of quaternary ammonium acid compound, to hydroxy acid is typically about 0.2 to about 30, for example, about 5 to about 25, or about 10 to about 20.
  • the composition has:
  • Optional ingredients that can be included in an antiperspirant and/or deodorant formulation of the antiperspirant compositions of the invention include solvents; water-soluble alcohols such as C 2 _s alcohols including ethanol; glycols including propylene glycol, dipropylene glycol, tripropylene glycol and mixtures thereof; glycerides including mono-, di- and triglycerides; medium to long chain organic acids, alcohols and esters; surfactants including emulsifying and dispersing agents; amino acids including glycine; structurants including thickeners and gelling agents, for example polymers, silicates and silicon dioxide; emollients; fragrances; and colorants including dyes and pigments.
  • solvents water-soluble alcohols such as C 2 _s alcohols including ethanol
  • glycols including propylene glycol, dipropylene glycol, tripropylene glycol and mixtures thereof
  • glycerides including mono-, di- and triglycerides
  • an antiperspirant and/or deodorant agent additional to the aluminum-zirconium salt or complex thereof can be included, for example an odor reducing agent such as a sulfur precipitating agent, e.g., copper gluconate, zinc gluconate, zinc citrate, etc.
  • an odor reducing agent such as a sulfur precipitating agent, e.g., copper gluconate, zinc gluconate, zinc citrate, etc.
  • the antiperspirant compositions can be formulated into topical antiperspirant and/or deodorant formulations suitable for application to skin, illustratively a stick, a gel, a cream, a roll-on, a soft solid, a powder, a liquid, an emulsion, a suspension, a dispersion or a spray.
  • the composition can comprise a single phase or can be a multi-phase system, for example a system comprising a polar phase and an oil phase, optionally in the form of a stable emulsion.
  • the composition can be liquid, semi-solid or solid.
  • the following topical formulations are provided for purposes of exemplification: [0032] In one prophetic example, the formulation is in the form of a spray that comprises:
  • g about 0.5% to about 3% by weight in total of at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof.
  • at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof.
  • the formulation is in the form of a roll-on that comprises:
  • At least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; and
  • the antiperspirant composition is present in the formulation in a polar phase, and the formulation further comprises an oil phase.
  • the formulation is in the form of a stick, wherein the polar phase comprises, by weight of the formulation:
  • At least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; and
  • the formulation is in the form of a stick, wherein the polar phase comprises, by weight of the formulation:
  • the formulation is in the form of a gel, wherein the polar phase comprises, by weight of the formulation:
  • the oil phase comprises, by weight of the formulation:
  • the formulation is in the form of a cream, wherein the polar phase comprises, by weight of the formulation:
  • oil phase comprises, by weight of the formulation:
  • the formulation is in the form of a roll-on, wherein the polar phase comprises, by weight of the formulation:
  • the oil phase comprises, by weight of the formulation:
  • the antiperspirant and/or deodorant formulation can be provided in any suitable container such as an aerosol can, tube or container with a porous cap, roll-on container, bottle, container with an open end, etc.
  • a method of the invention for controlling perspiration comprises applying to skin an antiperspirant effective amount of a formulation of any embodiment embraced or specifically described herein.
  • a method of the invention for controlling odor from perspiration comprises applying to skin a deodorant effective amount of a formulation of any embodiment embraced or specifically described herein.
  • At least one aluminum-zirconium salt or complex thereof is mixed with at least one betaine component in an aqueous medium; and at least one calcium salt and at least one hydroxy acid are added to the resulting mixture to form the composition.
  • Selection of particular aluminum-zirconium, betaine, calcium salt and hydroxy acid components and amounts of these components used can be made in accordance with the disclosure above.
  • the salt or complex is mixed with at least one betaine component in an aqueous medium; and at least one calcium salt and at least one hydroxy acid are added to the resulting mixture.
  • At least one betaine component in an aqueous medium
  • at least one calcium salt and at least one hydroxy acid are added to the resulting mixture.
  • composition components are by weight based on a total composition or formulation weight of 100%.
  • the ingredients for use in the compositions and formulations of the present invention are cosmetically acceptable ingredients.
  • cosmetically acceptable is meant suitable for use in a formulation for topical application to human skin.
  • a cosmetically acceptable excipient for example, is an excipient which is suitable for external application in the amounts and concentrations contemplated in the formulations of this invention, and includes for example excipients which are "Generally
  • pKa means the pKa in dilute aqueous solution at room temperature and pressure, e.g., at ca. 25°C, using standard, art-recognized measuring techniques.
  • the pKa for purposes of this application refers to the ionization equilibrium with respect to the first hydrogen dissociation step.
  • the pKa of lactic acid for purposes as defined herein would be about 3.86 and glycolic acid would be about 3.83.
  • compositions and formulations as provided herein are described and claimed with reference to their ingredients, as is usual in the art. As would be evident to one skilled in the art, the ingredients may in some instances react with one another, so that the true composition of the final formulation may not correspond exactly to the ingredients listed. Thus, it should be understood that the invention extends to the product of the combination of the listed ingredients.
  • Varying combinations OfCaCl 2 and/or hydroxy acids are added to a 25% solution of zirconium-aluminum chlorohydrex with betaine (R309; herein "ZAB").
  • ZAB zirconium-aluminum chlorohydrex with betaine
  • Table 1 shows data for SEC peaks 1, 3, 4 and 5 for each sample solution. Adjusted area is calculated using total aluminum peak area (sum of peaks 2-5) as the common denominator.

Abstract

An antiperspirant composition comprising a mixing product of at least one salt chosen from at least one aluminum salt, at least one aluminum-zirconium salt, at least one aluminum salt complex, and at least one aluminum-zirconium salt complex; at least one cosmetically acceptable hydroxy acid; and at least one cosmetically acceptable quaternary ammonium acid compound.

Description

ANTIPERSPIRANT COMPOSITIONS
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. Provisional Patent Application No. 60/737,207, filed on 16 November 2005, which is incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Antiperspirant compositions containing aluminum or aluminum-zirconium salts tend to exhibit polymerization of these salts over time, forming species with molecular weights ranging from about 500 to about 500,000 g/mol. In general, lower molecular weight species have greater antiperspirant effect than higher molecular weight species. Without being bound by theory, it is believed that the smaller molecules more readily and more effectively occlude sweat pores, thereby producing the desired antiperspirant effect. Thus, reducing the size of the polymers enhances the antiperspirant effect and moreover lowers the amount of antiperspirant salt that is necessary to control perspiration. The ability to reduce the amount of antiperspirant salt in a formulation without compromising efficacy would bring several advantages. Antiperspirant salts are a relatively expensive component of a typical antiperspirant formulation. It is thus very desirable to have compositions wherein antiperspirant salts are stabilized to reduce polymerization.
[0003] The extent of antiperspirant polymerization can be measured by size exclusion chromatography (SEC), also known as gel filtration chromatography (GFC). Passage of small molecules through an SEC column is retarded while large molecules pass through more rapidly. Elution time of a polymeric substance migrating through the SEC column is correlated with the size of the polymer molecules, and this relationship allows the apparent molecular weight of a polymer to be determined. In most cases, 4 to 6 well defined groups of polymerized species in aluminum or aluminum-zirconium salt compositions can be identified by SEC and are commonly known as peaks 1, 2, 3, 4, 5, and 6 (6 is not always present). Peak 1 is associated with zirconium species and so is present only for aluminum-zirconium salts. Peak 2 is not always present in the case of aluminum-zirconium salts. Peak 6 is not always present. The earlier peaks (1, 2, and 3) correspond to the larger species and the later peaks (4, 5 and 6) correspond to the smaller and more desirable species. Peaks correlate with weight average values of molecular weight for polymers, not as discrete values. [0004] There remains a need in the art for improved antiperspirant and/or deodorant compositions. In particular, it would be desirable to provide such compositions having improved stability. It would further be desirable to provide such compositions having enhanced antiperspirant efficacy. It would still further be desirable to provide such compositions wherein formation of higher molecular weight zirconium and/or aluminum polymeric species is reduced or suppressed, particularly where such reduction or suppression leads to enhanced efficacy, for example related to more effective occlusion of sweat pores.
SUMMARY OF THE INVENTION [0005] An antiperspirant composition comprising a mixing product of:
(a) at least one salt chosen from at least one aluminum salt, at least one aluminum-zirconium salt, at least one aluminum salt complex, and at least one aluminum-zirconium salt complex;
(b) at least one cosmetically acceptable hydroxy acid; and
(c) at least one cosmetically acceptable quaternary ammonium acid compound.
DETAILED DESCRIPTION OF THE INVENTION
[0006] As used throughout, ranges are used as a shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. [0007] In one embodiment, the antiperspirant composition comprises a mixing product of:
(a) an aluminum and/or aluminum-zirconium salt or a complex thereof;
(b) a cosmetically acceptable hydroxy acid, and
(c) a cosmetically acceptable quaternary ammonium acid compound.
[0008] The components of antiperspirant composition may be present in free or salt form, and depending on the formulation, may be precipitated or dissolved or in the form of solvates. [0009] The aluminum or aluminum-zirconium salts may be present for example in chloride or chlorohydrate form, e.g. , aluminum chloride, aluminum chlorohydrate, aluminum sequichlorohydrate, aluminum dichlorohydrate, aluminum zirconium tricchlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium octachlorohydrate, or mixtures thereof. Optionally, these salts may form or be provided as complexes with other compounds, for example complexes with the hydroxy acids and/or quaternary ammonium acids as described, and/or amino acids, such as glycine, and/or polyhydric alcohols, e.g., ethylene glycol, polyethylene glycol, propylene glycol, or polypropylene glycol. When the antiperspirant comprises an aluminum-zirconium salt, the salt may, for example, have a molar ratio of aluminum to zirconium of about 2 to about 10, for example, about 2 to about 5, or about 5 to about 10. In some embodiments comprising an aluminum-zirconium salt, the aluminum-zirconium salt may for example be an aluminum- zirconium chlorohydrate salt or complex thereof, wherein the molar ratio of (Aluminum and Zirconium) to chloro atoms is about 0.9 to about 2.1, for example, about 1.2 to about 1.8. [0010] The quaternary ammonium acid compound typically exists in zwitterionic form, forming an inner salt between cationic quaternary ammonium portion and the anionic carboxylic acid portion. It may however be present in salt form, e.g., acid addition salt form. For example betaine may be provided in the form of betaine hydrochloride.
[0011] The divalent metal cation may be provided in salt or oxide form, for example calcium may be provided in the form of, e.g., calcium chloride or calcium oxide. [0012] In one embodiment of the antiperspirant composition, the antiperspirant salt is an aluminum-zirconium chlorohydrate salt and the quaternary ammonium acid is betaine, wherein the metal (Aluminum and Zirconium) to chloride ratio is about 0.9 to about 2.1, the betaine to zirconium ratio is about 0.1 to about 2, and the betaine to hydroxy acid ratio is about 0.2 to about 30.
[0013] In one embodiment, the composition exhibits improved stability compared to analogous formulations lacking a hydroxy acid or lacking a hydroxy acid and a divalent cation, e.g., as measured by at least one of (a) a reduction in formation of higher molecular weight polymerized aluminum and/or zirconium species as indicated at least by reduction in area of SEC peaks 2 and/or 3 and/or increase in area of SEC peaks 4 and/or 5; (b) a reduction in formation of higher molecular weight polymerized zirconium species as indicated at least by reduction in area of SEC peak 1; or (c) an increase in peak 5 as compared to peak 4. For example, compositions when analyzed by SEC as a 5% aqueous solution using conditions capable of resolving the Aluminum and/or Zirconium species into at least 4 successive peaks, in one embodiment, exhibit a ratio of the SEC area of the first major peak (peak 1, largest polymer) to the SEC area of the last major peak (usually peak 5) of less than about 1 , and in another embodiment of less than about 0.25. [0014] There is further provided a method for controlling perspiration, the method comprising applying to skin an antiperspirant effective amount of the antiperspirant compositions as described above.
[0015] There is still further provided a process for preparing a stabilized antiperspirant composition, or for stabilizing an aluminum or aluminum zirconium antiperspirant salt or complex thereof, the process comprising:
(i) mixing at least one aluminum salt, at least one aluminum-zirconium salt, at least one aluminum salt complex, and/or at least one aluminum-zirconium salt complex with at least one quaternary ammonium acid component in an aqueous medium; and (ii) adding to the resulting mixture at least one hydroxy acid (and optionally a divalent cation) to form the composition.
[0016] In other embodiments, there is provided antiperspirant compositions obtained or obtainable by the foregoing process.
[0017] In another embodiment, there is provided an antiperspirant and/or deodorant formulation for topical use, comprising at least one stabilized antiperspirant compositions in combination with a cosmetically acceptable carrier. Such formulations may be as known in the art, e.g., in the form of a stick, gel, cream, liquid roll-on, or aerosol spray. Examples of formulations comprising the stabilized antiperspirant compositions of the invention are provided below.
[0018] SEC peak areas are used as indicators of aluminum and zirconium polymer size in antiperspirant salt solutions. It is believed, without being bound by theory, that enhanced antiperspirant and/or deodorant efficacy is associated with increase in peak 4 and/or peak 5 area relative to peak 2 and/or peak 3 area, and with decrease in peak 1 area, indicating a lower degree of polymerization of the aluminum and zirconium species respectively. Relative areas of peaks 1 through 5 constitute the "SEC profile", as that term is used herein, of an antiperspirant and/or deodorant composition. Stabilized compositions of the invention maintain, over a period of time, improved SEC profiles, indicating a lower degree of polymerization of the aluminum and/or zirconium species after aging, by comparison with non-stabilized compositions, for example compositions lacking a calcium salt and/or a hydroxy acid.
[0019] Peak areas can be adjusted based on an internal standard, with total aluminum peak area (sum of peaks 2 through 5) as the common denominator. This is possible as total aluminum peak area remains constant. Adjusting peak areas to an internal standard in this fashion better reflects the polymer distribution in the sample.
[0020] In certain embodiments, the relative amounts of components (a), (b), and (c) of the antiperspirant composition as described above can be such that an aqueous solution of these components in the same relative amounts, at a 25% concentration of (a) + (b), following aging of the solution at about 45°C for about 60 days, has an adjusted SEC peak 1 area of no more than about 40%, for example no more than about 20%, or no more than about 10%.
[0021] Illustratively, the relative amounts of components (a), (b), and (c) as described above are such that an aqueous solution of these components in the same relative amounts, at a 25% concentration of (a) + (b), following aging of the solution at about 450C for about 60 days, has an adjusted SEC peak 5 area of at least about 30%, for example at least about 40%.
[0022] In certain embodiments, the relative amounts of components (a), (b), and (c) as described above are such that an aqueous solution of these components in the same relative amounts, at a 25% concentration of (a) + (b), following aging of the solution at about 450C for about 60 days, has an adjusted SEC peak 4 area of at least about 15%. The adjusted SEC peak 4 area is optionally not more than about 25%.
[0023] In the composition according to one embodiment of the invention, the relative amounts of components (a), (b), and (c) as described above are such that an aqueous solution of these components in the same relative amounts, at a 25% concentration of (a) + (b), following aging of the solution at about 45°C for about 60 days, has:
(i) an adjusted SEC peak 1 area of no more than about 40%, for example no more than about
20%, or no more than about 10%;
(ii) an adjusted SEC peak 5 area of at least about 30%, for example at least about 40%; and (iii) an adjusted SEC peak 4 area of at least about 15%.
[0024] In certain embodiments, the aluminum or aluminum-zirconium salt of the antiperspirant compositions of the invention can be present in the final topical formulation in any suitable total amount, typically about 4% to about 35%, for example about 10% to about 25%, or about 15% to about 20%, by weight of the formulation. It will be understood that while amounts in various ranges of aluminum salts, aluminum-zirconium salts or complexes thereof are indicated herein, lesser amounts can be used to contribute to deodorant activity of deodorant products which are not classified as antiperspirants. [0025] The antiperspirant compositions of the invention also comprise a quaternary ammonium acid compound, e.g., an alpha — quaternary ammonium-carboxylic acid, for example, betaine. Betaine is l-carboxy-N,N5N-trimethylmethanaminium hydroxide inner salt (IUPAC nomenclature), and is zwitterionic. It occurs naturally in many foodstuffs and can also be synthesized. Though sometimes incorrectly referred to as an amino acid, it will be understood that betaine is not truly an amino acid. A "betaine component" herein can be betaine or a salt thereof. In certain embodiments, the betaine component comprises betaine, betaine hydrochloride or a mixture thereof. The betaine component may, for example, be present in the final formulation for topical use in a total amount of about 0.5 to about 20% for example about 5% to about 15%, by weight. In one embodiment, when the composition comprises an aluminum-zirconium salt, the molar ratio of betaine to zirconium may be about 0.1 to about 2, for example, about 0.1 to about 1.
[0026] The composition of the invention may also optionally comprise at least one divalent cation, e.g. in the form of a salt. In one embodiment, this cation is a calcium salt or oxide, e.g., calcium chloride, calcium bromide, calcium nitrate, calcium acetate, calcium formate, calcium gluconate, calcium ascorbate, calcium lactate, calcium glycinate, calcium citrate, calcium carbonate, calcium oxide, calcium hydroxide, calcium phosphate, calcium phosphonate, calcium picrolonate, calcium sulfate, calcium sulfonate, calcium sulfocyanate, calcium perrhenate or mixtures thereof. In certain embodiments, the calcium salt comprises an anion having a linear or branched Ci_6o alkyl or alkenyl chain and at least one functional moiety capable of binding a calcium ion. The at least one functional moiety can be a nitrate, sulfate, sulfonate, carbonate, carbonyl, phosphate, phosphonate or hydroxyl moiety. The anion can comprise one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, such heteroatoms being part of the chain and/or part of the functional moiety. In one embodiment, when the divalent cation is provided in the form of a salt, it may be present in the final formulation in a total amount of about 0.2% to about 10%, for example about 2% to about 8%, by weight. In one embodiment, the molar ratio of the divalent metal ion to the aluminum or (Aluminum and Zirconium) may be about 0.02 to about 1.2, for example about 0.1 to about 0.8. [0027] The composition also comprises at least one hydroxy acid. Illustrative hydroxy acids include α-hydroxy acids, β-hydroxy acids and mixtures thereof. In certain embodiments, the hydroxy acid is chosen from lactic acid, glycolic acid, lactobionic acid, carnitine, salicylic acid and mixtures thereof. In certain embodiments, the alpha-hydroxy acid has a pIQ of about 4.5 or less, about 2.5 to about 4.5, or about 3.5 to about 4.0.
[0028] In certain embodiments, the at least one hydroxy acid is present in a total amount of about 0.2% to about 10%, for example about 0.5% to about 9%, or about 2% to about 8%, by weight. In certain embodiments, the molar ratio of quaternary ammonium acid compound, to hydroxy acid is typically about 0.2 to about 30, for example, about 5 to about 25, or about 10 to about 20.
[0029] In certain embodiment, the composition has:
(i) a molar ratio of (Aluminum and Zirconium) to halo atoms in the at least one aluminum- zirconium salt or complex thereof of about 0.9 to about 2.1; (ii) a molar ratio of aluminum to zirconium of about 2 to about 10; (iii) a molar ratio of calcium to (Aluminum and Zirconium) of about 0.02 to about 1.2; (iv) a molar ratio of betaine to zirconium of about 0.1 to about 2; and (v) a molar ratio of betaine to hydroxy acid of about 0.2 to about 30. [0030] Optional ingredients that can be included in an antiperspirant and/or deodorant formulation of the antiperspirant compositions of the invention include solvents; water-soluble alcohols such as C2_s alcohols including ethanol; glycols including propylene glycol, dipropylene glycol, tripropylene glycol and mixtures thereof; glycerides including mono-, di- and triglycerides; medium to long chain organic acids, alcohols and esters; surfactants including emulsifying and dispersing agents; amino acids including glycine; structurants including thickeners and gelling agents, for example polymers, silicates and silicon dioxide; emollients; fragrances; and colorants including dyes and pigments. If desired, an antiperspirant and/or deodorant agent additional to the aluminum-zirconium salt or complex thereof can be included, for example an odor reducing agent such as a sulfur precipitating agent, e.g., copper gluconate, zinc gluconate, zinc citrate, etc.
[0031] The antiperspirant compositions can be formulated into topical antiperspirant and/or deodorant formulations suitable for application to skin, illustratively a stick, a gel, a cream, a roll-on, a soft solid, a powder, a liquid, an emulsion, a suspension, a dispersion or a spray. The composition can comprise a single phase or can be a multi-phase system, for example a system comprising a polar phase and an oil phase, optionally in the form of a stable emulsion. The composition can be liquid, semi-solid or solid. The following topical formulations are provided for purposes of exemplification: [0032] In one prophetic example, the formulation is in the form of a spray that comprises:
(a) about 4% to about 25% by weight in total of at least one aluminum-zirconium chlorohydrate salt or complex thereof;
(b) about 0.5 to about 20% by weight in total of at least one betaine component;
(c) about 0.2% to about 10% by weight in total of at least one calcium salt;
(d) about 0.2% to about 10% by weight in total of at least one hydroxy acid;
(e) about 35% to about 87% by weight of water;
(f) about 3% to about 7% by weight in total of at least one water soluble emollient; and
(g) about 0.5% to about 3% by weight in total of at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof.
[0033] In another prophetic example, the formulation is in the form of a roll-on that comprises:
(a) about 4% to about 25% by weight in total of at least one aluminum-zirconium chlorohydrate salt or complex thereof;
(b) about 0.5 to about 20% by weight in total of at least one betaine component;
(c) about 0.2% to about 10% by weight in total of at least one calcium salt;
(d) about 0.2% to about 10% by weight in total of at least one hydroxy acid;
(e) about 27% to about 88% by weight of water;
(f) about 0.5% to about 3% by weight in total of at least one magnesium aluminum silicate;
(g) about 0.5% to about 10% by weight in total of at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; and
(h) 0% to about 5% by weight in total of at least one water miscible solvent.
[0034] In certain embodiments, the antiperspirant composition is present in the formulation in a polar phase, and the formulation further comprises an oil phase.
[0035] In another prophetic example, the formulation is in the form of a stick, wherein the polar phase comprises, by weight of the formulation:
(a) about 4% to about 30% in total of at least one aluminum-zirconium chlorohydrate salt or complex thereof;
(b) about 0.5% to about 20% in total of at least one betaine component;
(c) about 0.2% to about 10% in total of at least one calcium salt;
(d) about 0.2% to about 10% in total of at least one hydroxy acid;
(e) about 5% to about 40% in total of water, one or more water miscible solvents, or a mixture thereof; and
(f) 0% to about 5% in total of at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; and the oil phase comprises, by weight of the formulation:
(g) about 0.5% to about 8.0% of a siloxane polyamide gelling agent; (h) about 20% to about 60% of a volatile organic or silicone based fluid;
(i) 0% to about 20% in total of at least one cosmetic ingredient selected from Cs-22 fatty alcohols, Ci2-36 fatty esters, Cs-is alkyl benzoates, linear polysiloxanes, and mixtures thereof;
Q) 0% to about 10% in total of at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; and
(k) 0% to about 3% of a fragrance.
[0036] In another prophetic example, the formulation is in the form of a stick, wherein the polar phase comprises, by weight of the formulation:
(a) about 4% to about 30% in total of at least one aluminum-zirconium chlorohydrate salt or complex thereof;
(b) about 0.5 to about 20% in total of at least one betaine component;
(c) about 0.2% to about 10% in total of at least one calcium salt;
(d) about 0.2% to about 10% in total of at least one hydroxy acid;
(e) about 5% to about 40% in total of water, one or more water miscible solvents, or a mixture thereof; and
(f) 0% to about 5% in total of at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; and the oil phase comprises, by weight of the formulation:
(g) about 20% to about 60% in total of one or more cosmetically acceptable solvents selected
C2_8 polyhydric alcohols, C8^22 unsaturated fatty alcohols, branched and straight chain Cg_
22 saturated fatty alcohols, and mixtures thereof; (h) 0% to about 10% in total of at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; (i) 0% to about 3 % of a fragrance; and
(j) about 5% to about 25% by weight of a Knoleic acid dimer based polyamide. [0037] In another prophetic example, the formulation is in the form of a gel, wherein the polar phase comprises, by weight of the formulation:
(a) about 4% to about 35% in total of at least one aluminum-zirconium chlorohydrate salt or complex thereof;
(b) about 0.5 to about 20% in total of at least one betaine component;
(c) about 0.2% to about 10% in total of at least one calcium salt;
(d) about 0.2% to about 10% in total of at least one hydroxy acid;
(e) about 25% to about 60% of water;
(f) about 5% to about 40% in total of at least one water miscible solvent; and
(g) 0% to about 5% in total of at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; and the oil phase comprises, by weight of the formulation:
(g) about 5% to about 20% by weight of a volatile organic fluid;
(h) about 0.5% to about 2% by weight of a dimethicone copolyol; and
(i) about 5% to about 20% by weight of a linear silicone.
[0038] In another prophetic example, the formulation is in the form of a cream, wherein the polar phase comprises, by weight of the formulation:
(a) about 4% to about 30% in total of at least one aluminum-zirconium chlorohydrate salt or complex thereof;
(b) about 0.5% to about 20% in total of at least one betaine component;
(c) about 0.2% to about 10% in total of at least one calcium salt; (d) about 0.2% to about 10% in total of at least one hydroxy acid; and
(e) about 40% to about 82% of water; and the oil phase comprises, by weight of the formulation:
(f) about 2% to about 10% of a volatile organic fluid;
(g) about 0.1% to about 3% of a monoglyceride, diglyceride, triglyceride, or mixture thereof; (h) about 4% to about 15% in total of at least one cosmetically acceptable surfactant selected cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; and
(i) about 3% to about 8% in total of at least one Cs-22 fatty alcohol.
[0039] In another prophetic example, the formulation is in the form of a roll-on, wherein the polar phase comprises, by weight of the formulation:
(a) about 4% to about 25% in total of at least one aluminum-zirconium chlorohydrate salt or complex thereof;
(b) about 0.5% to about 20% in total of at least one betaine component;
(c) about 0.2% to about 10% in total of at least one calcium salt;
(d) about 0.2% to about 10% in total of at least one hydroxy acid;
(e) about 30% to about 50% of water;
(f) about 5% to about 40% in total of at least one water miscible solvent; and
(g) 0% to about 2% in total of at least one cosmetically acceptable surfactant selected from cationic surfactants, nonionic surfactants, anionic surfactants, amphoteric surfactants, dimethicone copolyols, polyether ethoxylates, and mixtures thereof; and the oil phase comprises, by weight of the formulation:
(h) about 20% to about 50% of a volatile organic or silicone based fluid; and
(i) about 0.5% to about 2% by weight of a dimethicone copolyol.
[0040] The antiperspirant and/or deodorant formulation can be provided in any suitable container such as an aerosol can, tube or container with a porous cap, roll-on container, bottle, container with an open end, etc.
[0041] A method of the invention for controlling perspiration comprises applying to skin an antiperspirant effective amount of a formulation of any embodiment embraced or specifically described herein.
[0042] A method of the invention for controlling odor from perspiration comprises applying to skin a deodorant effective amount of a formulation of any embodiment embraced or specifically described herein.
[0043] In a process of the invention for preparing an antiperspirant and/or deodorant composition or formulation, at least one aluminum-zirconium salt or complex thereof is mixed with at least one betaine component in an aqueous medium; and at least one calcium salt and at least one hydroxy acid are added to the resulting mixture to form the composition. Selection of particular aluminum-zirconium, betaine, calcium salt and hydroxy acid components and amounts of these components used can be made in accordance with the disclosure above.
[0044] In a process of the invention for stabilizing a composition or formulation comprising an aluminum-zirconium salt or complex thereof, the salt or complex is mixed with at least one betaine component in an aqueous medium; and at least one calcium salt and at least one hydroxy acid are added to the resulting mixture. Selection of particular aluminum-zirconium, betaine, calcium salt and hydroxy acid components and amounts of these components used can be made in accordance with the disclosure above.
[0045] Unless stated otherwise, all percentages of composition components given in this specification are by weight based on a total composition or formulation weight of 100%.
[0046] Unless otherwise specifically identified, in one embodiment, the ingredients for use in the compositions and formulations of the present invention are cosmetically acceptable ingredients. By "cosmetically acceptable" is meant suitable for use in a formulation for topical application to human skin. A cosmetically acceptable excipient, for example, is an excipient which is suitable for external application in the amounts and concentrations contemplated in the formulations of this invention, and includes for example excipients which are "Generally
Recognized as Safe" (GRAS) by the United States Food and Drug Administration.
[0047] For purposes of this application, pKa means the pKa in dilute aqueous solution at room temperature and pressure, e.g., at ca. 25°C, using standard, art-recognized measuring techniques. For acids that have more than one hydrogen capable of dissociation and so have multiple pKa values, the pKa for purposes of this application refers to the ionization equilibrium with respect to the first hydrogen dissociation step. Thus the pKa of lactic acid for purposes as defined herein would be about 3.86 and glycolic acid would be about 3.83.
[0048] The compositions and formulations as provided herein are described and claimed with reference to their ingredients, as is usual in the art. As would be evident to one skilled in the art, the ingredients may in some instances react with one another, so that the true composition of the final formulation may not correspond exactly to the ingredients listed. Thus, it should be understood that the invention extends to the product of the combination of the listed ingredients.
EXAMPLE
[0049] Varying combinations OfCaCl2 and/or hydroxy acids (lactic acid or glycolic acid) are added to a 25% solution of zirconium-aluminum chlorohydrex with betaine (R309; herein "ZAB"). The resulting sample solution is then aged for two months at 45°C before analysis by SEC using a refractive index detector. Table 1 shows data for SEC peaks 1, 3, 4 and 5 for each sample solution. Adjusted area is calculated using total aluminum peak area (sum of peaks 2-5) as the common denominator.
Table 1 : Adjusted SEC peak areas following aging
Figure imgf000014_0001
[0050] Addition of 2% lactic acid decreases peak 1 area from 25.74% (ZAB alone) to 8.57%, and in presence of CaCl2 from 31.92% (ZAB + CaCl2) to 8.80%. This indicates that lactic acid can reduce polymerization of zirconium species. Glycolic acid does not reduce peak 1 area in this study.
[0051] Addition of 2% lactic acid increases peak 5 area from 25.19% (ZAB alone) to 42.18%, and in presence OfCaCl2 from 25.07% (ZAB + CaCl2) to 43.16%. Similarly, addition of 2% glycolic acid increases peak 5 area from 25.19% (ZAB alone) to 45.32%, and in presence OfCaCl2 from 25.07% (ZAB + CaCl2) to 43.09%. These results indicate that hydroxy acids such as lactic acid and glycolic acid can reduce polymerization of aluminum species.

Claims

WHAT IS CLAIMED IS:
1. An antiperspirant composition comprising a mixing product of:
(a) at least one salt chosen from at least one aluminum salt, at least one aluminum- zirconium salt, at least one aluminum salt complex, and at least one aluminum- zirconium salt complex;
(b) at least one cosmetically acceptable hydroxy acid; and
(c) at least one cosmetically acceptable quaternary ammonium acid compound.
2. The composition of claim 1 , wherein the salt is a chlorohydrate.
3. The composition of claim 2, wherein the salt is chosen from aluminum-zirconium pentachlorohydrate, aluminum-zirconium octachlorohydrate, aluminum-zirconium tetrachlorohydrate, aluminum-zirconium trichlorohydrate, and mixtures thereof.
4. The composition of claim 1 , wherein the cosmetically acceptable hydroxy acid comprises at least one alpha-hydroxy acid.
5. The composition of claim 4, wherein the alpha-hydroxy acid has a pKa of less than about 4.5.
6. The composition of claim 4, wherein the alpha-hydroxy acid is chosen from lactic acid, glycolic acid, and combinations thereof.
7. The composition of claim 1 , wherein the cosmetically acceptable hydroxy acid comprises at least one beta-hydroxy acid.
8. The composition of claim 1 , wherein the beta-hydroxy acid is chosen from carnitine, salicylic acid, and combinations thereof.
9. The composition of claim 1, wherein the quaternary ammonium acid compound comprises betaine.
10. The composition of claim 1 further comprising a divalent metal cation.
11. The composition of claim 105 wherein the divalent metal cation is calcium.
12. The composition of claim 1 further comprising a calcium salt chosen from calcium chloride, calcium oxide, and mixtures thereof.
13. The composition of claim 1 , wherein the aluminum or aluminum-zirconium salt comprises an aluminum-zirconium chlorohydrate salt and the quaternary ammonium acid comprises betaine, wherein the metal (Aluminum and Zirconium) to chloride ratio on a molar basis for the salt is about 0.9 to about 2.1.
14. The composition of claim 13, wherein the betaine to zirconium ratio on a molar basis is about 0.1 to about 2.
15. The composition of claim 13, wherein the betaine to hydroxy acid ratio on a molar basis is about 0.2 to about 30.
16. The composition of claim 11 , wherein the ratio of calcium to metal (Aluminum and Zirconium) on a molar basis is about 0.02 to about 1.2.
17. The composition of claim 1, wherein the composition comprises less than about 1% by weight of an amino acid.
18. The composition of claim 1 , which when analyzed by SEC as a 5% aqueous solution using conditions capable of resolving the Aluminum and/or Zirconium species into at least 4 successive peaks, the ratio of the SEC area of the first major peak to the SEC area of the last major peak is less than about 1.
19. The composition of claim 18, wherein the ratio of the SEC area of the first major peak to the SEC area of the last major peak is less than about 0.25.
20. A composition comprising the stabilized antiperspirant composition of claim 1 in combination with a cosmetically acceptable carrier.
21. A method for controlling perspiration comprising applying to skin a formulation comprising an antiperspirant effective amount of the composition of claim 1.
22. A method for controlling odor from perspiration comprising applying to skin a deodorant effective amount of the composition of claim 1.
23. A process for preparing or stabilizing the antiperspirant composition of claim 1 comprising: i. mixing the at least one salt with the at least one quaternary ammonium acid component in an aqueous medium; and ii. adding to the resulting mixture at least one hydroxy acid to form the composition.
PCT/US2006/060987 2005-11-16 2006-11-16 Antiperspirant compositions WO2007059530A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0618736-6A BRPI0618736A2 (en) 2005-11-16 2006-11-16 methods, methods for the control of perspiration, and odor of perspiration, and, process for the preparation or stabilization of antiperspirant composition
AU2006315119A AU2006315119B2 (en) 2005-11-16 2006-11-16 Antiperspirant compositions
CA2629042A CA2629042C (en) 2005-11-16 2006-11-16 Antiperspirant compositions
ES06846328.0T ES2442252T3 (en) 2005-11-16 2006-11-16 Antiperspirant compositions
EP06846328.0A EP1948317B1 (en) 2005-11-16 2006-11-16 Antiperspirant compositions
PL06846328T PL1948317T3 (en) 2005-11-16 2006-11-16 Antiperspirant compositions
ZA2008/04051A ZA200804051B (en) 2005-11-16 2008-05-12 Antiperspirant compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73720705P 2005-11-16 2005-11-16
US60/737,207 2005-11-16

Publications (2)

Publication Number Publication Date
WO2007059530A2 true WO2007059530A2 (en) 2007-05-24
WO2007059530A3 WO2007059530A3 (en) 2007-07-19

Family

ID=37964123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/060987 WO2007059530A2 (en) 2005-11-16 2006-11-16 Antiperspirant compositions

Country Status (12)

Country Link
US (2) US20070110687A1 (en)
EP (2) EP2324815A1 (en)
AR (1) AR058191A1 (en)
AU (1) AU2006315119B2 (en)
BR (1) BRPI0618736A2 (en)
CA (1) CA2629042C (en)
CL (1) CL2006003116A1 (en)
ES (1) ES2442252T3 (en)
PL (1) PL1948317T3 (en)
RU (2) RU2384320C2 (en)
WO (1) WO2007059530A2 (en)
ZA (2) ZA200804051B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087702A3 (en) * 2009-12-23 2012-07-05 Colgate-Palmolive Company Aqueous antiperspirant/deodorant composition
WO2015055200A1 (en) * 2013-10-15 2015-04-23 Henkel Ag & Co. Kgaa Cosmetic antiperspirants with alkylsulphonic acids
WO2015055199A3 (en) * 2013-10-15 2015-08-06 Henkel Ag & Co. Kgaa Antiperspirant cosmetic agents having alpha-hydroxy acids

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109833A1 (en) 2002-12-09 2004-06-10 Xiaozhong Tang High efficacy, low irritation aluminum salts and related products
US7704531B2 (en) * 2005-02-18 2010-04-27 Colgate-Palmolive Company Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine
US20100202993A1 (en) * 2007-12-12 2010-08-12 Long Pan Antiperspirant Active Compositions Having SEC Chromatogram Exhibiting High SEC Peak 4 Intensity
US8257689B2 (en) 2007-12-12 2012-09-04 Colgate-Palmolive Company Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
CA2717536A1 (en) * 2008-03-14 2009-09-17 Ernest Bloom Antiperspirant compositions containing a copper salt and methods of using
US20090257970A1 (en) * 2008-03-14 2009-10-15 Ernest Bloom Antiperspirant compositions containing a copper salt and a penetration enhancer and methods of using the same
EP2462061B1 (en) * 2009-08-06 2017-05-31 Colgate-Palmolive Company Method of making an antiperspirant active composition having sec chromatogram exhibiting high sec peak 4 intensity
EP2482790B1 (en) * 2009-09-30 2017-09-27 Colgate-Palmolive Company Antiperspirant composition
US9144695B2 (en) 2010-06-01 2015-09-29 Coty Inc. Antiperspirant compositions
US9463985B2 (en) 2010-11-02 2016-10-11 Colgate-Palmolive Company Aluminum salt containing high percentage of Al30
AU2010363348B2 (en) 2010-11-02 2014-07-31 Colgate-Palmolive Company Antiperspirant active compositions and manufacture thereof
AU2011366870B2 (en) 2011-04-26 2014-10-30 Colgate-Palmolive Company Antiperspirant active compositions and manufacture thereof
CA2834129A1 (en) 2011-04-26 2012-11-01 Colgate-Palmolive Company Compositions containing polyhydroxyoxoaluminum cations and manufacture thereof
FR3008407B1 (en) * 2013-07-10 2017-01-27 Oreal ESTER AND GLYCINE BETAINE AMIDE DERIVATIVES AS DEODORANT ASSETS, COSMETIC COMPOSITIONS THAT INCLUDE THEM
DE102013220779A1 (en) * 2013-10-15 2015-04-16 Henkel Ag & Co. Kgaa Antiperspirant cosmetic products containing lactates
WO2016048340A1 (en) * 2014-09-26 2016-03-31 Colgate-Palmolive Company Aluminum chlorohydrate salts exhibiting high sec peak 1
DE102018213831A1 (en) * 2018-08-16 2020-02-20 Henkel Ag & Co. Kgaa "Carnitine or its salts as an active ingredient to reduce sweat secretion"
US20220079857A1 (en) * 2020-09-14 2022-03-17 Assured Hygiene Products Ltd. Preparation for treating body odor

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509253A (en) * 1967-02-28 1970-04-28 Pennwalt Corp Aluminum chloride-aluminum chlorohydroxide complex antiperspirant composition
US4025615A (en) * 1975-02-25 1977-05-24 Armour Pharmaceutical Company Antiperspirant complexes formed with alkali metal and ammonium zirconyl carbonates
FR2303536A1 (en) * 1975-03-11 1976-10-08 Rhone Poulenc Ind NEW ALUMINUM SALTS, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
US4359456A (en) * 1976-01-14 1982-11-16 Lever Brothers Company Antiperspirant activity of basic aluminum compounds
US4435382A (en) * 1980-07-14 1984-03-06 Bristol-Myers Company Anhydrous alcoholic antiperspirant suspension composition containing certain aluminum or aluminum/zirconium salt glycine complexes
US4331609A (en) * 1980-09-08 1982-05-25 The Procter & Gamble Company Antiperspirant composition
US4675177A (en) * 1980-10-09 1987-06-23 American Cyanamid Company Antiperspirant compositions
US5589196A (en) * 1983-08-16 1996-12-31 The Gillette Company Antiperspirant composition
US4775528A (en) * 1983-08-16 1988-10-04 The Gillette Company Antiperspirant composition
GB8410403D0 (en) * 1984-04-24 1984-05-31 Unilever Plc Antiperspirant product
US4871525A (en) * 1986-10-24 1989-10-03 Westwood Chemical Corporation Antiperspirant composition and method of preparation
CA2046170A1 (en) * 1990-07-10 1992-01-11 Morton Lawrence Barr Basic aluminum antiperspirant active materials having enhanced activity, antiperspirant active compositions containing such materials, and methods for preparation of such materials and compositions
DE4039063A1 (en) * 1990-12-07 1992-06-11 Wella Ag HAIR CURING IN THE FORM OF A MICROEMULSION
US5225187A (en) * 1991-02-15 1993-07-06 Somerville Technology Group, Inc. Process for preparing concentrated aluminum-zirconium solutions
RU2056833C1 (en) * 1992-02-06 1996-03-27 Людмила Максимовна Козлова Vitaminized deodorant
EP0571677A1 (en) * 1992-05-29 1993-12-01 Unilever Plc Aqueous parfume oil microemulsions
DE4309372C2 (en) * 1993-03-23 1997-08-21 Beiersdorf Ag Cosmetic deodorants containing mixtures of wool wax acids or wool wax acid components and fatty acid partial glycerides of unbranched fatty acids
FR2718022B1 (en) * 1994-04-01 1996-04-26 Roussel Uclaf Cosmetic or dermatological compositions and their preparation.
US5516511A (en) * 1994-05-06 1996-05-14 The Procter & Gamble Company Antiperspirant gel compositions comprising chelators
US5643558A (en) * 1994-11-02 1997-07-01 The Gillette Company Method of making polyhydric alcohol solutions of enhanced efficacy antiperspirant actives
US5653970A (en) * 1994-12-08 1997-08-05 Lever Brothers Company, Division Of Conopco, Inc. Personal product compositions comprising heteroatom containing alkyl aldonamide compounds
US5599533A (en) * 1994-12-15 1997-02-04 Estee Lauder, Inc. Stable water-in-oil emulsion system
DE19509079A1 (en) * 1995-03-15 1996-09-19 Beiersdorf Ag Cosmetic or dermatological microemulsions
ZA966814B (en) * 1995-08-18 1998-02-12 Colgate Palmolive Co Clear cosmetic gel composition.
DE19641672A1 (en) * 1996-10-10 1998-04-16 Beiersdorf Ag Cosmetic or dermatological preparations based on ethylene oxide-free and propylene oxide-free emulsifiers for the production of microemulsion gels
US5997850C1 (en) * 1997-10-29 2001-11-27 Colgate Palmolive Co Antiperspirant actives and formulations made therefrom
US6682749B1 (en) * 1998-04-03 2004-01-27 Colgate-Palmolive Company Low Residue cosmetic composition
US6042816A (en) * 1998-08-19 2000-03-28 The Gillette Company Enhanced antiperspirant salts stabilized with calcium and concentrated aqueous solutions of such salts
DE19842787A1 (en) * 1998-09-18 2000-03-23 Beiersdorf Ag Emulsifier-free finely dispersed systems of the oil-in-water and water-in-oil type
DE19855935A1 (en) * 1998-12-04 2000-06-08 Beiersdorf Ag Use of functionally substituted betaines as antiperspirants
DE19919481A1 (en) * 1999-04-29 2000-11-02 Beiersdorf Ag Stable, effective against blemished skin and acne active ingredient combinations containing surface active glucose derivatives and hydroxycarboxylic acids
CA2373630A1 (en) * 1999-05-11 2000-11-16 Charles Walton Champ Host-guest processes and formulations for delivering bio-affecting compounds
US20040228887A1 (en) * 1999-05-11 2004-11-18 Champ Charles W. Host-guest processes and formulations for delivering bio-affecting compounds
US6024945A (en) * 1999-07-29 2000-02-15 Reheis, Inc. Antiperspirant compositions for aerosol formulations
US6126928A (en) * 1999-08-24 2000-10-03 The Procter & Gamble Company Compositions containing solubilized, acid-enhanced antiperspirant active
DE19949826A1 (en) * 1999-10-15 2001-04-19 Beiersdorf Ag Cosmetic and dermatological light protection formulations in the form of O / W macroemulsions or O / W microemulsions, containing dihydroxyacetone
US6265364B1 (en) * 1999-12-28 2001-07-24 Colgate-Palmolive Company Solid cleansing composition comprising a choline salt
EP1184027B1 (en) * 2000-09-01 2005-08-17 Cognis IP Management GmbH Cosmetic stick composition
US6375937B1 (en) * 2000-10-20 2002-04-23 Colgate-Palmolive Company Antiperspirant salts for enhanced cosmetic products
US6436381B1 (en) * 2000-10-25 2002-08-20 The Gillette Company Aluminum-zirconium antiperspirant salts with high peak 5 al content
US6608126B2 (en) * 2000-12-18 2003-08-19 Dow Corning Corporation Silicone liquid crystals, vesicles, and gels
AU766418B2 (en) * 2001-04-20 2003-10-16 Goldschmidt Gmbh Compositions for controlling microorganisms, comprising primary and secondary esters of polyglycerol in an effective ratio
PL364079A1 (en) * 2001-06-01 2004-12-13 Henkel Kommanditgesellschaft Auf Aktien Arylsulfatase-inhibitors in deodorants and antiperspirants
DE10154368A1 (en) * 2001-11-06 2003-05-15 Henkel Kgaa Beta-glucuronidase inhibitors in deodorants and antiperspirants
US6726901B2 (en) * 2002-05-09 2004-04-27 The Gillette Company Stabilized antiperspirant compositions containing aluminum-zirconium salts with low M:Cl ratio
WO2004012694A1 (en) * 2002-08-02 2004-02-12 The Gillette Company Clear personal care compositions containing visible capsules
US20040091436A1 (en) * 2002-11-12 2004-05-13 Zijun Li Antiperspirant compositions of enhanced efficacy containing strontium
US20040109833A1 (en) * 2002-12-09 2004-06-10 Xiaozhong Tang High efficacy, low irritation aluminum salts and related products
US6911195B2 (en) * 2002-12-16 2005-06-28 The Gillette Company Gel antiperspirant composition containing volatile linear silicone and calcium enhanced antiperspirant salt
US20040198998A1 (en) * 2003-04-04 2004-10-07 Marian Holerca Glycine-free antiperspirant salts with betaine for enhanced cosmetic products
RU2346932C2 (en) * 2003-04-04 2009-02-20 Колгейт-Палмолив Компани Glycine-free antiperspirant salts with betaine for improvement of cosmetic goods quality
US7105691B2 (en) * 2003-06-26 2006-09-12 Colgate-Palmolive Company Aluminum / zirconium / glycine antiperspirant actives stabilized with Betaine
US8524256B2 (en) * 2003-06-27 2013-09-03 Air Products And Chemicals, Inc. Deodorant cosmetic composition comprising at least one semicrystalline polymer
DE10332928A1 (en) * 2003-07-19 2005-02-03 Beiersdorf Ag Antitranspirantgel
US6923952B2 (en) * 2003-08-14 2005-08-02 The Gillette Company Enhanced efficacy antiperspirant compositions containing strontium or calcium
US6902723B2 (en) * 2003-08-14 2005-06-07 The Gillette Company Enhanced efficacy antiperspirant compositions containing strontium
US6942850B2 (en) * 2003-08-15 2005-09-13 The Gillette Company Aqueous alcoholic antiperspirant composition containing calcium enhanced antiperspirant salt
US20050053631A1 (en) * 2003-09-10 2005-03-10 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method of decreasing sebum production
GB0326181D0 (en) * 2003-11-11 2003-12-17 Unilever Plc Antiperspirant compositions
US6902724B1 (en) * 2004-03-24 2005-06-07 Reheis, Inc. Enhanced efficacy basic aluminum halides, antiperspirant active compositions and methods for making
US7014843B2 (en) * 2004-03-24 2006-03-21 Reheis, Inc. Enhanced efficacy basic aluminum halides/metal cation salt, antiperspirants actives and compositions containing such materials and methods for making
DE102004015025A1 (en) * 2004-03-26 2005-10-13 Clariant Gmbh Basic aluminum halide complexes
DE102005017032B4 (en) * 2004-04-27 2009-12-17 Beiersdorf Ag Cosmetic formulation containing mandelic acid
US7087220B2 (en) * 2004-05-28 2006-08-08 Reheis, Inc. High pH antiperspirant compositions of enhanced efficacy
US7704531B2 (en) * 2005-02-18 2010-04-27 Colgate-Palmolive Company Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine
FR2884414B1 (en) * 2005-04-19 2007-06-15 Oreal COSMETIC DEODORANT COMPOSITION COMPRISING THE ASSOCIATION OF ZINC SALICYLATE OR ONE OF ITS DERIVATIVES AND AN ANTI-TRANSPARENT ALUMINUM SALT
US20070020211A1 (en) * 2005-07-22 2007-01-25 Reheis, Inc. Betaine with Calcium and/or Strontium Antiperspirants
DE102005055519A1 (en) * 2005-11-18 2007-08-30 Beiersdorf Ag Optically attractive antiperspirant formulation
US20070196303A1 (en) * 2006-02-17 2007-08-23 Reheis, Inc. Stable buffered aluminum compositions having high hplc bands iii and iv containing calcium/strontium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087702A3 (en) * 2009-12-23 2012-07-05 Colgate-Palmolive Company Aqueous antiperspirant/deodorant composition
US8557228B2 (en) 2009-12-23 2013-10-15 Colgate-Palmolive Company Aqueous antiperspirant composition
US8663610B2 (en) 2009-12-23 2014-03-04 Colgate-Palmolive Company Method of making an anhydrous liquid antiperspirant composition
US8815222B2 (en) 2009-12-23 2014-08-26 Colgate—Palmolive Company Anhydrous liquid antiperspirant composition
US9585825B2 (en) 2009-12-23 2017-03-07 Colgate-Palmolive Company Method of making an anhydrous liquid antiperspirant composition
WO2015055200A1 (en) * 2013-10-15 2015-04-23 Henkel Ag & Co. Kgaa Cosmetic antiperspirants with alkylsulphonic acids
WO2015055199A3 (en) * 2013-10-15 2015-08-06 Henkel Ag & Co. Kgaa Antiperspirant cosmetic agents having alpha-hydroxy acids
US20160199287A1 (en) * 2013-10-15 2016-07-14 Henkel Ag & Co. Kgaa Cosmetic antiperspirants with alkylsuphonic acids
US10357446B2 (en) 2013-10-15 2019-07-23 Henkel Ag & Co. Kgaa Cosmetic antiperspirants with alkylsuphonic acids

Also Published As

Publication number Publication date
ZA201305658B (en) 2014-11-26
AU2006315119A1 (en) 2007-05-24
AR058191A1 (en) 2008-01-23
EP1948317B1 (en) 2013-10-16
PL1948317T3 (en) 2014-03-31
RU2009142879A (en) 2011-05-27
US20110014144A1 (en) 2011-01-20
ZA200804051B (en) 2013-10-30
AU2006315119B2 (en) 2010-01-28
CL2006003116A1 (en) 2008-02-29
EP2324815A1 (en) 2011-05-25
ES2442252T3 (en) 2014-02-10
US20070110687A1 (en) 2007-05-17
RU2008123790A (en) 2009-12-27
RU2519341C2 (en) 2014-06-10
WO2007059530A3 (en) 2007-07-19
BRPI0618736A2 (en) 2013-01-08
EP1948317A2 (en) 2008-07-30
CA2629042C (en) 2013-05-21
CA2629042A1 (en) 2007-05-24
RU2384320C2 (en) 2010-03-20

Similar Documents

Publication Publication Date Title
AU2006315119B2 (en) Antiperspirant compositions
CA2534203C (en) Enhanced efficacy antiperspirant compositions containing strontium or calcium
CA2785000C (en) Aqueous antiperspirant composition
JP4074193B2 (en) Antiperspirant products
MXPA04011010A (en) Stabilized antiperspirant compositions containing aluminum-zirconium salts with low m:cl ratio -.
AU2012351041B2 (en) Anhydrous antiperspirant compositions
WO2020187699A1 (en) An antiperspirant composition comprising reactive salts
US20220054374A1 (en) An antiperspirant composition comprising inorganic polyionic cluster
WO2019118351A1 (en) Zirconium-based cluster as an antiperspirant and deodorant active

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2629042

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006315119

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/006149

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006846328

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006315119

Country of ref document: AU

Date of ref document: 20061116

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 08057430

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2008123790

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06846328

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0618736

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080516